189 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
patients with moderately to severely active ulcerative colitis (UC), and long-term safety results from the Phase 3 U-ENDURE trial of Rinvoq in adult … announced an interim analysis of an ongoing 156-week extension study that supports the long-term safety, tolerability and efficacy of Qulipta
8-K
EX-1.1
ox144o2 hv65vyz3lkmd
26 Feb 24
Other Events
5:08pm
424B5
aqj9n
26 Feb 24
Prospectus supplement for primary offering
6:12am
424B5
6ktc75c4
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
oe2tin fn2uv8
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
EX-99.1
iv49cp
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
EX-99.1
7dpkb0xuk
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
EX-99.1
p0sj 72i1yme23e
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.2
zuiu m25dmx96a5
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
i50egybe48abqi
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
a1vvyiwc973mc9p
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am